LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report

Scientific discussion

Morfin Kalceks
(morphine hydrochloride)

SE/H/1616/01/MR

This module reflects the scientific discussion for the approval of Morfin Kalceks. The procedure was finalised at 2014-09-11. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se

I. INTRODUCTION

The application for Morfin Kalceks, 10 mg/ml, solution for injection, is a generic application made according to Article 10(1) of Directive 2001/83/EC. The applicant, Pilum Pharma AB, applies for a marketing authorisation in Sweden through the National Procedure.

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Morfin Meda, 10 mg/ml, solution for injection authorised in Sweden since 1973, with Meda AB as marketing authorisation holder.

For approved indications, see the Summary of Product Characteristics.

II. QUALITY ASPECTS

II.1 Introduction

Morfin Kalceks is presented in the form of solution for injection containing 10 mg of morphine hydrochloride which corresponds to 7.6 mg of morphine. The excipients are hydrochloric acid and water form injections. The solution for injection is filled in glass ampoules.

II.2 Drug Substance

Morphine hydrochloride has a monograph in the Ph. Eur.

Morphine hydrochloride is a white, or almost white, crystalline powder or colourless, silky needles or cubical masses which is freely/poorly soluble in water, slightly soluble in ethanol 96 %, practically insoluble in toluene. The structure of morphine hydrochloride has been adequately proven and its physico-chemical properties sufficiently described. Relevant information is presented. The route of synthesis has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The active substance specification includes relevant tests and the limits for impurities/degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies under ICH conditions have been conducted and the data provided are sufficient to confirm the retest period.

II.3 Medicinal Product

Morfin Kalceks solution for injection is formulated using excipients described in the current Ph Eur. All raw materials used in the product has demonstrated compliance with Commission Directive 2003/63/EC and the NfG on Minimising the risk of transmitting Animal Spongiform Encephalopathy Agents via human and veterinary medicinal products (EMEA/410/01).

The product development has taken into consideration the physico-chemical characteristics of the active substance.

The manufacturing process has been sufficiently described and critical steps identified. Results from the process validation studies confirm that the process is under control and ensure both batch to batch reproducibility and compliance with the product specification.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies under ICH conditions have been performed and data presented support the shelf life and storage conditions claimed in the SPC.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

According to the Guideline on the investigation of Bioequivalence (CHMP/QWP/EWP/1401/98 Rev. 1) no bioequivalence study is necessary for parenteral solutions if the test product is to be administered as an aqueous intravenous solution containing the same active substance as the currently approved product. In addition, no bioequivalence studies are required for other parenteral routes, if the test product is of the same type of solution (aqueous or oily), contains the same concentration of the same active substance and the same excipients in similar amounts as the medicinal product currently approved. Moreover, a bioequivalence study is not required for an aqueous parenteral solution with comparable excipients in similar amounts, if it can be demonstrated that the excipients have no impact on the viscosity.

Morfin Kalceks is a parenteral solution, intended for intravenous administration as well as administration via other parenteral routes (subcutaneous and intramuscular), containing the same active substance in the same concentration as the currently authorised product. There are differences in excipients between the test and reference product. However, it is considered unlikely that the differences should significantly affect the viscosity of the solution or the bioavailability following intramuscular or subcutaneous injection.

Thus, the absence of bioequivalence studies is considered acceptable for this product.

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

User consultation

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to Morfin Abcur SE/H/1354/01/MR which was User tested and accepted in IB-variation 5.4.3:2013-5864. The bridging report submitted by the applicant has been found acceptable.

The risk/benefit ratio is considered positive and Morfin Kalceks is recommended for approval.

VI. APPROVAL

Morfin Kalceks was approved in the national procedure on 2014-09-11.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse
SE/H/1616/01/MR	Initial Mutual Recognition Procedure	Yes	2016-09-21	Approval	N/A

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se